Last updated: September 27, 2026
WAL ZYR D is an over-the-counter extended-release combination containing cetirizine hydrochloride 5 mg and pseudoephedrine hydrochloride 120 mg per 12-hour tablet. Its commercial value is driven less by active-ingredient patent protection than by reliable extended-release performance, low-cost tablet manufacture, retail compliance, and management of pseudoephedrine sales restrictions. Exact inactive ingredients can vary by private-label manufacturer and NDC; public product labels generally identify a conventional tablet system using cellulose, lactose, crospovidone or related disintegrants, povidone, silicon dioxide, magnesium stearate, and hypromellose-type film-coating materials.[1]
What is WAL ZYR D and how is it regulated?
WAL ZYR D is a store-brand equivalent of the cetirizine-pseudoephedrine 12-hour combination commonly marketed under Zyrtec-D. The standard strength is:
| Attribute |
Product profile |
| Active ingredients |
Cetirizine HCl 5 mg; pseudoephedrine HCl 120 mg |
| Dosage form |
Extended-release oral tablet |
| Dosing interval |
One tablet every 12 hours |
| Therapeutic category |
Antihistamine and nasal decongestant |
| Primary indications |
Seasonal allergic rhinitis and perennial allergic rhinitis symptoms |
| Typical age labeling |
Adults and children 12 years and older |
| Regulatory route |
OTC monograph framework or equivalent approved labeling |
| Prescription requirement |
No prescription, but pseudoephedrine sales controls apply |
| Biosimilar relevance |
None |
Cetirizine reduces histamine-mediated allergy symptoms. Pseudoephedrine produces systemic nasal decongestion through sympathomimetic activity. The formulation challenge is to maintain pseudoephedrine release over approximately 12 hours while preserving tablet manufacturability and acceptable cetirizine dissolution.
What excipients are likely used in WAL ZYR D?
Public labels for cetirizine-pseudoephedrine extended-release tablets commonly list the following excipient functions:
| Excipient category |
Typical materials |
Commercial purpose |
| Diluent or filler |
Lactose monohydrate, microcrystalline cellulose |
Provides tablet mass and compression strength |
| Binder |
Povidone |
Improves granule and tablet integrity |
| Disintegrant |
Crospovidone, sodium starch glycolate, or croscarmellose sodium |
Supports breakup of the immediate-release portion |
| Glidant |
Colloidal silicon dioxide |
Improves powder flow |
| Lubricant |
Magnesium stearate |
Reduces sticking and ejection force |
| Release-control polymer |
Hypromellose or related hydrophilic polymer |
Controls pseudoephedrine release |
| Coating materials |
Hypromellose, polyethylene glycol, titanium dioxide, colorants |
Supports swallowability, identification, and handling |
| Processing aids |
Purified water and volatile granulation solvents |
Manufacturing aids that normally do not remain in the finished product |
The exact WAL ZYR D composition should be treated as NDC-specific. Private-label products can use the same active ingredients and dose while changing nonfunctional colorants, coating systems, fillers, or tablet-process aids.
Which excipients control the 12-hour release profile?
The main release-control variables are polymer grade, polymer concentration, tablet porosity, compression force, particle size, and drug-to-polymer ratio. A hydrophilic matrix based on hypromellose can hydrate after ingestion and form a gel barrier that slows pseudoephedrine diffusion.
A formulation team should control:
- Initial release during the first one to two hours.
- Release consistency through the middle of the dosing interval.
- Residual release at approximately 10 to 12 hours.
- Sensitivity to food, agitation, and gastrointestinal pH.
- Dose dumping risk if the tablet is split, crushed, or chewed.
Cetirizine may be incorporated into an immediate-release fraction, while pseudoephedrine is placed in a controlled-release matrix. A bilayer tablet or coated multiparticulate design can separate those functions, but it carries more manufacturing complexity than a single matrix tablet.
What excipient strategy is commercially optimal?
The lowest-risk strategy is a conventional, monolithic extended-release tablet using widely available compendial excipients. This approach minimizes raw-material qualification, process-transfer risk, and regulatory review burden.
Cost-minimization strategy
A cost-focused formulation would use:
- Microcrystalline cellulose and lactose as primary fillers.
- Povidone as a standard binder.
- A widely available hypromellose grade as the release-control polymer.
- Magnesium stearate and colloidal silicon dioxide for routine tableting performance.
- A simple film coat with limited colorant complexity.
This design supports high-speed compression and broad supplier availability. The principal risks are variability in polymer hydration, tablet hardness, and pseudoephedrine dissolution.
Premium reliability strategy
A higher-value formulation could use:
- A more tightly specified hypromellose grade.
- Direct-compression excipients with controlled particle-size distribution.
- A moisture-barrier coating.
- Low-dusting, high-hardness tablets.
- Packaging with enhanced humidity protection.
This strategy can reduce batch-to-batch dissolution variation and improve shelf-life performance. The economic benefit is strongest where retail returns, recalls, or supply interruptions carry significant cost.
Differentiated delivery strategy
A company could develop a bilayer or multiparticulate system with separate immediate-release cetirizine and extended-release pseudoephedrine components. Potential benefits include tighter control of each active ingredient and improved flexibility for future strengths.
The disadvantages are higher tooling, validation, content-uniformity, and scale-up costs. A differentiated architecture is more commercially defensible when it produces a measurable benefit, such as improved food-effect performance or lower peak-related adverse effects.
What FDA and Orange Book status applies to WAL ZYR D?
WAL ZYR D is an OTC product, and its regulatory position differs from a conventional prescription generic.
The FDA OTC monograph system permits marketing when the product conforms to applicable monograph conditions, including active ingredients, dosages, indications, warnings, directions, and labeling. Cetirizine and pseudoephedrine products are subject to FDA OTC requirements, while pseudoephedrine is also subject to federal retail controls under the Combat Methamphetamine Epidemic Act.[2][3]
The Orange Book primarily identifies approved prescription drug products, relevant patents, and therapeutic-equivalence information. OTC monograph products generally do not receive the same Orange Book patent-listing treatment as prescription NDAs. As a result, WAL ZYR D ordinarily would not have an Orange Book patent estate comparable to a prescription branded drug.[4]
Does WAL ZYR D require a Paragraph IV challenge?
Usually no. A Paragraph IV certification is an ANDA mechanism used to challenge listed patents associated with an approved reference listed drug. A private-label OTC monograph product can enter without filing an ANDA when it complies with the applicable monograph and other FDA requirements.
A Paragraph IV pathway could become relevant if a company pursued an approved NDA, 505(b)(2) application, or a new proprietary delivery system with listed patents. It is not the normal route for a standard cetirizine-pseudoephedrine OTC monograph product.
When does WAL ZYR D lose exclusivity?
WAL ZYR D has no meaningful current composition-of-matter exclusivity. Cetirizine and pseudoephedrine are long-established active ingredients. The foundational cetirizine patent estate expired years ago, and pseudoephedrine has long been available in generic and OTC forms.
| Exclusivity category |
Status |
| Cetirizine composition patent |
Expired |
| Pseudoephedrine composition protection |
Expired |
| Standard combination exclusivity |
No current meaningful barrier identified |
| OTC monograph exclusivity |
Not a conventional patent exclusivity right |
| Pediatric exclusivity |
Not applicable to the standard store-brand product |
| Orphan exclusivity |
Not applicable |
| Biosimilar exclusivity |
Not applicable |
| Formulation patents |
Must be assessed by specific product and jurisdiction |
The remaining commercial protection is operational rather than exclusivity-based. It includes retailer shelf position, supply reliability, pricing, packaging recognition, distribution access, and the ability to satisfy pseudoephedrine tracking requirements.
What formulation patents protect cetirizine-pseudoephedrine products?
Potential patent claims could cover:
- A specific extended-release matrix.
- A bilayer tablet.
- A coated-particle or multiparticulate system.
- A particular dissolution profile.
- A manufacturing process that reduces dose dumping.
- A moisture-protective coating.
- A combination of excipients at defined concentration ranges.
- A method of treating allergic rhinitis with a specified dosing regimen.
For a conventional WAL ZYR D equivalent, these claims are unlikely to create a durable barrier unless they are tied to a genuinely differentiated formulation and remain enforceable in the target jurisdiction. A freedom-to-operate review must examine active patents, expired patents, terminal disclaimers, patent-family continuity, prosecution history, and claim scope. The product name alone does not identify a complete patent estate.
What manufacturing and intellectual-property barriers exist?
The principal barrier is controlled-release performance, not active-ingredient access.
Manufacturing risks
The main technical risks are:
- Pseudoephedrine content uniformity in a high-dose matrix.
- Inconsistent polymer hydration.
- Tablet sticking during compression.
- Capping or lamination at high compression force.
- Dissolution shifts caused by lubricant overmixing.
- Moisture-related changes in hardness and release.
- Failure of the tablet to maintain release after coating or packaging.
- Unacceptable food-effect or alcohol-effect behavior.
Pseudoephedrine’s relatively high dose increases the importance of blend uniformity and tablet weight control. A formulation that uses excessive polymer can produce incomplete release or poor tablet size. Insufficient polymer can create an early release spike.
Intellectual-property risks
A new entrant should evaluate:
- Active formulation patents in the United States and major export markets.
- Patent claims directed to controlled-release pseudoephedrine.
- Trade-secret manufacturing parameters.
- Proprietary excipient grades and supplier restrictions.
- Trademark rights surrounding WAL ZYR D and Zyrtec-D.
- Packaging and trade-dress restrictions.
- State-specific pseudoephedrine distribution requirements.
Expired patents may still provide useful technical information, but they do not create an enforceable exclusion right.
Which companies are challenging the market?
The market is populated by national brands, pharmacy private labels, mass-retail store brands, and generic OTC manufacturers. Competitive products commonly use the same 5 mg/120 mg active-ingredient strength.
Competition is based on:
- Retail price.
- Product availability.
- Store-brand placement.
- Packaging clarity.
- Tablet count and multipack economics.
- Pseudoephedrine purchasing convenience.
- Supply continuity.
- Consumer familiarity with cetirizine.
The most credible commercial threat to WAL ZYR D is substitution by another private-label product, not a biosimilar or a patent-based generic launch. Retailers can shift sourcing between qualified manufacturers if the product remains monograph-compliant and meets dissolution and stability specifications.
What commercial opportunities exist for excipient suppliers and manufacturers?
The strongest opportunities are incremental.
1. Private-label supply
Manufacturers can offer retailer-specific products with common tablet cores and customized coatings, labels, and packaging. A shared platform can reduce development costs across multiple customers.
2. Excipient substitution
A supplier can create value by qualifying alternate sources for hypromellose, microcrystalline cellulose, lactose, or disintegrants. Dual sourcing reduces supply risk, but each substitution requires comparability testing, especially for dissolution.
3. Improved moisture protection
A more robust coating and high-barrier blister or bottle system can reduce stability failures in humid distribution environments. This is commercially relevant for national retail networks.
4. Manufacturing efficiency
Direct compression, continuous blending, optimized lubrication, and high-throughput coating can reduce cost per tablet. The formulation must retain dissolution performance after scale-up.
5. New dosage forms
Potential extensions include orally disintegrating or chewable cetirizine-pseudoephedrine products, although pseudoephedrine taste, dose size, and 12-hour release requirements make these technically difficult. A lower-dose pediatric product would require separate regulatory and clinical evaluation rather than a simple excipient change.
What generic launch risks exist for WAL ZYR D?
Generic entry risk is high because the active ingredients are old, widely available, and not protected by meaningful composition patents. The practical risks are:
| Risk |
Impact |
| Retail price erosion |
High |
| Competing private-label sourcing |
High |
| Pseudoephedrine inventory controls |
Medium to high |
| Controlled-release failure |
High during development |
| Patent litigation |
Low for a standard monograph product |
| Biosimilar substitution |
None |
| Manufacturing supply disruption |
Medium |
| Regulatory labeling error |
Medium to high |
A successful entrant needs a reliable tablet process, validated dissolution testing, compliant pseudoephedrine distribution, and a retailer acquisition strategy. A patent-centered launch plan is unlikely to create a durable advantage.
How does WAL ZYR D compare with Zyrtec-D?
| Factor |
WAL ZYR D |
Zyrtec-D |
| Active ingredients |
Cetirizine HCl and pseudoephedrine HCl |
Same active combination |
| Standard strength |
5 mg/120 mg |
5 mg/120 mg |
| Commercial position |
Store brand |
National brand |
| Primary advantage |
Lower price and retailer access |
Brand recognition |
| Patent advantage |
None apparent for standard product |
Historical brand and formulation rights, where applicable |
| Regulatory model |
OTC product framework |
OTC product framework |
| Key differentiation |
Price, availability, packaging |
Consumer familiarity and marketing |
| Biosimilar risk |
None |
None |
| Main competitive threat |
Other private labels |
Store brands and generic OTC products |
Key Takeaways
- WAL ZYR D is a 5 mg cetirizine hydrochloride and 120 mg pseudoephedrine hydrochloride extended-release OTC tablet.
- The commercial formulation priority is controlled pseudoephedrine release, not protection of the active ingredients.
- A conventional excipient platform using cellulose, lactose, povidone, disintegrant, lubricant, glidant, and hypromellose is the lowest-risk approach.
- Exact inactive ingredients must be assessed at the NDC level because private-label manufacturers can vary excipients and coatings.
- The product is generally governed by OTC requirements and pseudoephedrine sales controls rather than an Orange Book patent strategy.
- Paragraph IV litigation is not the normal entry mechanism for a standard OTC monograph equivalent.
- The strongest commercial opportunities are private-label supply, dual sourcing, moisture protection, manufacturing efficiency, and retailer-specific packaging.
- Biosimilar risk is irrelevant. The primary threat is substitution by other private-label or generic OTC manufacturers.
FAQs
Is WAL ZYR D the same as Zyrtec-D?
It is generally the same active-ingredient combination and strength, but the inactive ingredients, manufacturer, tablet appearance, packaging, and manufacturing process may differ.
Can WAL ZYR D tablets be crushed or split?
Extended-release tablets should not be crushed or chewed because doing so may alter pseudoephedrine release. Tablet-splitting instructions must come from the approved product labeling.
Does WAL ZYR D have an Orange Book-listed patent?
A standard OTC monograph product generally is not treated like a prescription NDA product with an Orange Book-listed patent estate. Product-specific patent review is still required for formulation and manufacturing claims.
Can a manufacturer replace hypromellose with another release-control polymer?
Yes, but the replacement can materially change dissolution, food effect, stability, and dose-dumping behavior. Comparative formulation and performance testing is required.
Is pseudoephedrine a barrier to national distribution?
Yes. Federal purchase limits, identification requirements, sales records, behind-the-counter handling, and state-specific rules increase distribution and compliance costs.[3]
References
- DailyMed. (n.d.). Cetirizine hydrochloride and pseudoephedrine hydrochloride extended-release tablet labeling. U.S. National Library of Medicine.
- U.S. Food and Drug Administration. (n.d.). OTC Monograph M016: Antihistamine drug products for over-the-counter human use.
- U.S. Drug Enforcement Administration. (n.d.). Combat Methamphetamine Epidemic Act requirements for retail sales of pseudoephedrine.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.
